PO.CL01.22 · 临床研究

Serum neuron-specific enolase (NSE) as a biomarker of central nervous system (CNS) metastases: Updated results from the BrainStorm program (Oncodistinct 006)

编号 1063 展板 3 时间 4/19 02:00–05:00 区域 Section 42 主讲 Nuria Kotecki, MD

分会场 Circulating Tumor Cells, Metastasis, and Dissemination Biology 1

该海报暂无可访问的完整资料 AACR 官方页面 ↗

作者与单位

Soraia Lobo-Martins¹, Diogo Martins-Branco¹, Luca Arecco¹, Guilherme Nader-Marta², Andrea Gombos³, Anthony Gonçalves⁴, Eleonora Stephane de Maio D’Esposito⁵, Philippe Barthelemy⁶, Vincent Vanhaudenarde⁷, Florian Clatot⁸, Stéphane Holbrechts⁹, Francois P. Duhoux¹⁰, Edith Borcoman¹¹, Elisabeth Pop¹², Damien Parlier¹², Claire Cheymol¹³, Joseph Gligorov¹⁴, Hannelore Denys¹⁵, Paul Clement¹⁶, Caroline Duhem¹⁷, Lore Decoster¹⁸, Jean-Luc Canon¹⁹, Nadège Kindt²⁰, Françoise Rothé²¹, Ahmad H. Awada²², Nuria Kotecki³

¹Academic Trials Promoting Team (ATPT), Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Brussels, Belgium,²Medical Oncology Department, Dana-Farber Cancer Institute, Boston, MA,³Medical Oncology Department, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Brussels, Belgium,⁴Medical Oncology, Institut Paoli-Calmettes, Marseille, France,⁵IUCT Oncopole-Institut Claudius Regaud, Toulouse, France,⁶Hôpitaux Universitaires de Strasbourg, Strasbourg, France,⁷Medical Oncology Department, CHU UCL Namur, site Ste-Elisabeth, Namur, Belgium,⁸Medical Oncology Department, Centre Henri Becquerel, Rouen, France,⁹CHU HELORA Hôpital de Mons site Kennedy, Mons, Belgium,¹⁰Medical Oncology Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium,¹¹Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France,¹²Clinical Trials Center (CTC), Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Brussels, Belgium,¹³Centre Oscar Lambret, Lille, France,¹⁴APHP Tenon, IUC-UPMC, Sorbonne University, Paris, France,¹⁵Ghent University Hospital, Gent, Belgium,¹⁶UZ Leuven Gasthuisberg, Leuven, Belgium,¹⁷Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg,¹⁸UZ Brussel, Brussels, Belgium,¹⁹Oncologie Médicale, Grand Hôpital de Charleroi, Charleroi, Belgium,²⁰Laboratory of Clinical and Experimental Oncology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Brussels, Belgium,²¹Breast Cancer Translational Research Laboratory, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Brussels, Belgium,²²Medical Oncology Department, Chirec Cancer Institute, Brussels, Belgium

摘要 Abstract

Background: Serum NSE, a marker of neuronal injury, may serve as a non-invasive indicator of early CNS involvement in solid tumors. Here, we explore the role of NSE for predicting development of CNS metastases. Methods: The BrainStorm program, is an ongoing international, multicenter prospective initiative, allowing the constitution of a large clinicopathological database and biobank to study CNS metastases. The program is recruiting patients (pts) with newly diagnosed non-CNS metastatic solid tumors at high risk of (Part A) or with CNS metastases (Part B and C). All pts undergo serologic NSE testing at baseline and at regular intervals pre- and post-CNS metastases. Main objective of the present analysis was to assess the role of baseline NSE as a predictive biomarker of CSN development from pts tested in Part A vs B, using Mann-Whitney test for group comparisons and logistic regression models to estimate OR. Results: 124 pts with available NSE results were included in the program from Nov/2020 to Jun/2025 (Part A, n=73; Part B, n=51) - Table 1. NSE levels were significatively higher in Part B than Part A (median 15.0 (IQR 12.8-24.3) vs 13.6 (IQR 11.4-16.4) ng/mL; p=0.017). In Part A, baseline NSE, as a continuous variable, was significantly associated with CNS metastases development (OR per ng/mL increase 1.12; 95% CI 1.02-1.22). Using the upper limit of normal as a categorical cut-off, baseline NSE showed a trend toward higher odds of CNS metastases (OR 2.84; 95%CI 0.60-13.39; 8 CNS events). Conclusions: These findings support a potential role for NSE as a non-invasive predictive biomarkers for the development of CNS metastases although confirmation in the fully accrued BrainStorm program is required. Table 1 - Baseline characteristics Part A (N=73) Part B (N=51) Age in years, median (IQR) 58 (48-66) 62 (56-68) Female, n (%) 65 (89) 40 (78) ECOG-PS, n (%) 0 40 (55) 10 (20) 1 27 (37) 28 (55) 2 4 (5) 9 (18) Cancer type, n (%) TNBC 12 (16) 8 (16) HER2+ BC 45 (62) 11 (22) ER+/HER2- BC - 11 (22) NSCLC 10 (14) 13 (25) SCLC 4 (5) 3 (6) Melanoma 2 (3) 0 (0) Other - 5 (10) No. metastatic sites, median (IQR) 2 (1-2) 2 (1-3) Months from non-CNS metastases to NSE, median (IQR) 206 (76-495) 178 (26-972) Weeks from CNS metastases to NSE, median (IQR) - 15 (10-26) Baseline serum NSE in ng/mL, median (IQR) 13.6 (11.4-16.4) 15.0 (12.8-24.3)

利益披露 Disclosure

S. Lobo-Martins, Roche ). AstraZeneca ). Novartis ). D. Martins-Branco, None. L. Arecco, Gilead ). AstraZeneca Travel. G. Nader-Marta, None.. A. Gombos, None.. A. Gonçalves, None.. E. Stephane de Maio D’Esposito, None.. P. Barthelemy, None.. V. Vanhaudenarde, None.. F. Clatot, None.. S. Holbrechts, None.. F. P. Duhoux, None.. E. Borcoman, None.. E. Pop, None.. D. Parlier, None.. C. Cheymol, None. H. Denys, PharmaMar Other, Consulting or Advisory Role. AstraZeneca Other, Consulting or Advisory Role. Eli Lilly Other, Consulting or Advisory Role. Novartis Other, Consulting or Advisory Role. Amgen Other, Consulting or Advisory Role. GSK Other, Consulting or Advisory Role. Seagen Other, Consulting or Advisory Role. MSD Other, Consulting or Advisory Role. Gilead Other, Consulting or Advisory Role. AbbVie Other, Consulting or Advisory Role. Menarini Other, Consulting or Advisory Role. Biopa Other, Consulting or Advisory Role. Incyclix Other, Consulting or Advisory Role. AstraZeneca Travel. MSD Travel. Gilead Travel. GSK Travel. Novartis Travel. P. Clement, None.. C. Duhem, None.. L. Decoster, None.. J. Canon, None.. N. Kindt, None.. F. Rothé, None.. A. H. Awada, None.. N. Kotecki, None.

在会议检索中打开